Corrigendum - Intimation regarding completion of term of Independent Directorship of Mr. Harish Pande and Mr. Arun Kumar.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has issued a corrigendum informing that the term of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar, has come to an end. As a result, both directors will step down from the board upon completion of their tenure. The corrigendum suggests there was a correction or clarification to an earlier intimation on the same matter. No reasons for non-reappointment or succession plan details were mentioned in this filing.
For shareholders, this means two independent directors are exiting the board simultaneously, which could temporarily weaken board oversight until new independent directors are appointed. The stock price is unlikely to be materially affected as term completions are routine corporate events.